DSPACE
25.1.2023 15:55:40 CET | Business Wire | Press release
On April 17, 2023, Dr. Carsten Hoff (49) will become the new CEO of the dSPACE group succeeding Martin Goetzeler (60), who is leaving his post at his own request and for personal reasons. To ensure a smooth handover, Martin Goetzeler will continue to be available to the new CEO in an advisory capacity after April 17, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005072/en/
From left to right, dSPACE founder and shareholder Dr. Herbert Hanselmann, Dr. Carsten Hoff and Martin Goetzeler. (Photo: Business Wire)
Dr. Carsten Hoff is a highly experienced manager, who is ideally suited to the tasks ahead at dSPACE. He comes from a research and development-centric background with a degree in electrical engineering and a doctorate in computer science. He has international management experience and is familiar with dSPACE and the company's products.
Dr. Carsten Hoff is currently Managing Director of CLAAS E-Systems. Prior to that, he worked in various management positions at the automotive supplier HELLA. He will use his extensive experience from previous positions to provide strategic impetus for dSPACE and to continue to drive forward the new topics of software-based simulation and validation.
"I am very pleased to be joining the dSPACE company. I am very impressed by the company's development and dSPACE's role in the automotive industry. The values that the family-owned company dSPACE stands for convinced me,” stated Dr. Carsten Hoff.
"Dr. Carsten Hoff, an internationally experienced and technically skilled manager who is very familiar with the current challenges in our target markets is taking the helm – I wish him a good start in the company and with our customers," said Dr. Herbert Hanselmann, founder and shareholder of dSPACE.
"Under Martin Goetzeler's successful leadership, dSPACE has sustainably strengthened its market position by setting a decisive course in terms of consistent portfolio expansion, globalization, and future-oriented structures. By continually expanding future investments and the team, he has succeeded in continuing the great growth rate at a high level of sales in challenging years," said Dr. Herbert Hanselmann, adding, "We regret but respect Martin Goetzeler's decision. I would like to expressly thank him for his important contribution, his extraordinary commitment, and the close cooperation based on trust."
"It has been an exciting five years. The excellent and close cooperation with the entire dSPACE team, our customers and partners, and the shareholder family was the key to success and motivation at all times. I would like to thank everyone very much for this," said Martin Goetzeler. "After a fulfilling professional career, I would like to devote more time to my personal and family tasks and interests in the future. I wish my successor and all dSPACE employees the necessary skills, much success, and all the best for the future," said Goetzeler.
Martin Goetzeler has led the dSPACE company since March 1, 2018. Portfolio expansions in virtual and real simulation and validation to cover market and customer requirements in a timely manner, especially in automated and autonomous driving and in the software-defined vehicle were important milestones during this time. In addition to the great importance of software-in-the-loop simulation in this process, technologies such as AI and cloud are now also being used in the products. At the same time, he systematically built up structures and processes to sustainably secure the strong global growth.
About dSPACE
dSPACE is a leading provider of simulation and validation solutions worldwide for developing networked, autonomous, and electrically powered vehicles. The company's range of end-to-end solutions are used particularly by automotive manufacturers and their suppliers to test the software and hardware components in their new vehicles long before a new model is allowed on the road. Not only is dSPACE a sought-after partner in vehicle development, engineers also rely on our know-how at dSPACE when it comes to aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With approximately 2,200 employees worldwide, dSPACE is headquartered in Paderborn, Germany, has three project centers in Germany, and serves customers through regional dSPACE companies in the USA, the UK, France, Japan, China, Croatia, and South Korea.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
